Previous studies have shown that Pargyline, a nonspecific inhibitor of LSD1, interfered with the EMT of prostate cancer in vivo, and the lysine-specific demethylase UTX inhibited EMT-induced breast cancer stem cell properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1 [32, 33]. The gene discussed is KDM1A; the disease is breast cancer.